OS Cancer Research Results
OS, overall survival: Click to Expand ⟱
| Source: |
| Type: |
Overall survival
|
Scientific Papers found: Click to Expand⟱
Risk∅, In this study, over a median of 8.6 years, LDA was not associated with incident cancer among older adults, but cancer mortality risk was significantly elevated.
OS∅, However, the elevated cancer mortality risk seen with aspirin for participants in the RCT period did not persist into the post-RCT observation period, suggesting no legacy effect.
Dose↝, 1550 participants with resected non-metastatic colorectal cancer from 11 countries or territories in Asia-Pacific and the Middle East were randomly assigned to receive daily aspirin 200 mg or placebo for 3 years.
OS∅, No significant differences were observed in 5-year disease-free survival or overall survival between the aspirin and placebo groups, with hazard ratios (HRs) of 0·91 (95% CI 0·73–1·13) for disease-free survival and 0·75 (0·53–1·07) for os
QoL↑, Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
OS∅,
OS∅, Huachansu when combined with gemcitabine did not improve the outcome of patients with locally advanced and/or metastatic pancreatic cancer.
other∅, No significant difference in disease progression was noted between the two groups at days 14 (p=0.33), 28 (p=0.67) or 56 (p=0.50).
OS∅, There was no difference in survival between both groups from study entry to censor date (p=0.38).
other∅, In this substudy analysis, treatment with CBD oil did not affect disease progression or survival over the course of 56 days in patients with advanced cancer.
PDK1↓, Dichloroacetate (DCA), a pyruvate dehydrogenase kinase metabolic inhibitor, reduces tumor lactate production and has been used in cancer therapy previously.
OS∅, end-of-treatment complete response rates were significantly higher in the DCA group compared to placebo (71.4% vs 37.5%, p = 0.0362), survival outcomes were not significantly different between groups.
lactateProd↓, significant drop in pyruvate (0.47, p <0.005) and lactate (0.61, p <0.005) in the DCA group.
toxicity↝, Adding DCA to cisplatin-based CRT appears safe with no detrimental effect on survival and expected metabolite changes compared to placebo.
FAO↑, DCA treated patients had enhanced fatty acid oxidation, and increased mitochondrial oxidation that may contribute to unique microbiome-related changes.
OS↑, a strong and significant inverse association was observed between bladder cancer mortality and broccoli intake
OS∅, There were no significant associations for total vegetables, total fruits, or other individual cruciferous vegetables.
OS∅, clinical trial of 88 patients with recurrent glioblastoma, the addition of disulfiram and copper to alkylating chemotherapy did not significantly improve survival at 6 months,
toxicity↑, Six patients (15%) in the experimental group developed elevated liver enzymes compared with no patient in the SOC group
*Dose↝, EPA at a dose of 2 g or 4 g daily or placebo
Weight↑, relative to placebo, mean weight increased by 1.2 kg with 2 g EPA (95% CI, 0 kg to 2.3 kg) and by 0.3 kg with 4 g EPA (
cachexia↓,
OS∅, no statistically significant improvements in survival, weight, or other nutritional variables.
Dose↝, Four hundred twenty-one assessable patients with cancer-associated wasting were randomly assigned to an EPA supplement 1.09 g administered bid plus placebo; MA liquid suspension 600 mg/d plus an isocaloric, isonitrogenous supplement administered twic
Weight↑, A smaller percentage taking the EPA supplement gained >or= 10% of baseline weight compared with those taking MA: 6% v 18%, respectively (P =.004).
eff↑, Combination therapy resulted in weight gain of >or= 10% in 11% of patients (P =.17 across all arms).
OS∅, Survival was not significantly different among arms.
QoL∅, Global quality of life was not significantly different among groups.
QoL↑, Patients in the melatonin-treated group had better adjusted HRQoL scores, with a slightly significantly better score (2.69 points, 95% confidence interval (CI)=0.01-5.38, p=0.049) being found in social well-being
OS∅, Median survival was 7.3 months (95% CI=3.42-11.14) without significant difference (lower survival in placebo group)
selectivity↑, A great amont of DNA damage marker was observed in the placebo-treated group, and this was associated with lower survival (r(2)=-0.656, p=0.02), implying the protective effect of melatonin in healthy cells.
Showing Research Papers: 1 to 11 of 11
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11
Pathway results for Effect on Cancer / Diseased Cells:
Core Metabolism/Glycolysis(tgid=4) ⓘ
FAO↑, 1, lactateProd↓, 1, PDK1↓, 1,
Transcription & Epigenetics(tgid=7) ⓘ
other∅, 2,
Drug Metabolism & Resistance(tgid=21) ⓘ
Dose↝, 2, eff↑, 1, selectivity↑, 1,
Functional Outcomes(tgid=23) ⓘ
cachexia↓, 1, OS↑, 1, OS∅, 11, QoL↑, 2, QoL∅, 1, Risk∅, 1, toxicity↑, 1, toxicity↝, 1, Weight↑, 2,
Total Targets: 16
Pathway results for Effect on Normal Cells:
Drug Metabolism & Resistance(tgid=21) ⓘ
Dose↝, 1,
Total Targets: 1
Scientific Paper Hit Count for: OS, overall survival
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:229 State#:% Dir#:6
wNotes=on sortOrder:rid,rpid
Home Page